PALVELLA THERAPEUTICS ($PVLA) posted quarterly earnings results for Q4 2025 on Tuesday, March 31st. The company reported earnings of -$1.08 per share, missing estimates of -$0.93 by $0.15. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market open this morning: +3.37%
You can see Quiver Quantitative's $PVLA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PALVELLA THERAPEUTICS Insider Trading Activity
PALVELLA THERAPEUTICS insiders have traded $PVLA stock on the open market 12 times in the past 6 months. Of those trades, 2 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $PVLA stock by insiders over the last 6 months:
- KATHLEEN GOIN (Chief Operating Officer) has made 0 purchases and 10 sales selling 21,510 shares for an estimated $2,055,146.
- GEORGE M JENKINS purchased 4,000 shares for an estimated $500,000
- ELAINE J HERON purchased 2,400 shares for an estimated $300,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PALVELLA THERAPEUTICS Hedge Fund Activity
We have seen 94 institutional investors add shares of PALVELLA THERAPEUTICS stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC added 354,525 shares (+1016.0%) to their portfolio in Q4 2025, for an estimated $37,108,131
- ADAMS STREET PARTNERS LLC removed 298,986 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,743,432
- STATE STREET CORP added 283,211 shares (+206.3%) to their portfolio in Q4 2025, for an estimated $29,643,695
- BVF INC/IL removed 282,240 shares (-24.3%) from their portfolio in Q4 2025, for an estimated $29,542,060
- JENNISON ASSOCIATES LLC added 280,573 shares (+262.4%) to their portfolio in Q4 2025, for an estimated $29,367,575
- ALLIANCEBERNSTEIN L.P. added 269,027 shares (+inf%) to their portfolio in Q4 2025, for an estimated $28,159,056
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 250,062 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,173,989
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PALVELLA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $PVLA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/25/2026
- Truist Securities issued a "Buy" rating on 12/16/2025
- Canaccord Genuity issued a "Buy" rating on 12/16/2025
- Clear Street issued a "Buy" rating on 12/05/2025
- Stifel issued a "Buy" rating on 11/24/2025
- Raymond James issued a "Strong Buy" rating on 11/19/2025
- Chardan Capital issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for PALVELLA THERAPEUTICS, check out Quiver Quantitative's $PVLA forecast page.
PALVELLA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $PVLA recently. We have seen 12 analysts offer price targets for $PVLA in the last 6 months, with a median target of $200.0.
Here are some recent targets:
- Andrew S. Fein from HC Wainwright & Co. set a target price of $270.0 on 03/24/2026
- Geulah Livshits from Chardan Capital set a target price of $210.0 on 03/16/2026
- Graig Suvannavejh from Mizuho set a target price of $250.0 on 02/25/2026
- Jeet Mukherjee from BTIG set a target price of $215.0 on 02/25/2026
- Whitney Ijem from Canaccord Genuity set a target price of $204.0 on 12/16/2025
- Danielle Brill from Truist Securities set a target price of $190.0 on 12/16/2025
- Ritu Baral from TD Cowen set a target price of $133.0 on 12/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
